So that you can become more acquainted with the Thuja team, every newsletter showcases an interview with a team member.
In the spotlight for this edition is the latest addition to our team. Evan Castiglia, he joined Thuja as of April 1st, as an Investment Director and Partner.
Prior to joining Thuja, Evan was Partner and Head of European Investments for Philips Ventures, the corporate venture capital group of Philips. During his tenure, Evan led and managed numerous investments across healthcare sectors, including medical device and digital health, and across investment stages from early to growth. Before joining Philips Ventures, Evan was the Chief Business Officer of the U.S.-based venture backed precision biology company, RareCyte, which he helped lead from product concept to international commercialization.
Let’s start this interview with what you enjoy most about the work you do.
I enjoy working with our portfolio company CEOs. Building a medtech or biopharma company from the early stages is a very difficult challenge, supporting those at the helm and helping them solve problems where I can is my favorite part of the job.
What do you like about working at Thuja?
The teamwork. Everyone on our team has a unique perspective and is empowered to contribute to each investment in our portfolio. I learn a lot from working side by side with everyone at Thuja.
What drives and motivates you?
We all know someone who has suffered greatly from poor health at some point in their life. Having a positive impact on the ability to provide better care to patients in the future is the single most important motivating factor for me.
And last but not least, what do you enjoy doing when you are not working?
Spending time with my kids. I have three wonderful children and they are growing up too fast. I also enjoy playing football and padel as much as I can.